OKYO Pharma (OKYO) Debt to Equity (2023 - 2025)

OKYO Pharma (OKYO) reported Debt to Equity of -$0.15 for Q1 2025, down 153.81% year-over-year from $0.29 in Q1 2024, and down 1243487.77% quarter-over-quarter from -$0.0 in Q3 2024.

OKYO Pharma (OKYO) Debt to Equity (2023 - 2025) Analysis & Trends

OKYO Pharma (OKYO) has 3 years of Debt to Equity data on file, last reported at -$0.15 in Q1 2025.

  • Debt to Equity for Q1 2025 came in at -$0.15, down 153.81% year-over-year; the trailing twelve-month figure through Mar 2025 was -$0.15 (down 153.81% YoY), and the FY2025 annual result was -$0.15, down 153.81% from the prior year.
  • Debt to Equity declined to -$0.15 in Q1 2025 per OKYO's latest filing, from -$0.0 in the prior quarter.
  • Over five years, Debt to Equity peaked at $0.0 in Q3 2023 and troughed at -$0.15 in Q1 2025.
  • A 3-year average of -$0.05 and a median of -$0.03 in 2024 frame the typical range for Debt to Equity.
  • The sharpest annual moves came in 2024 and 2025: Debt to Equity plunged 100.33% in 2024, then sank 153.81% in 2025.
  • A 3-year view of Debt to Equity shows it stood at $0.0 in 2023, then sank by 100.33% to -$0.0 in 2024, then sank by 1243487.77% to -$0.15 in 2025.
  • Business Quant data shows OKYO's Debt to Equity at -$0.15 in Q1 2025, -$0.0 in Q3 2024, and -$0.06 in Q1 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Alterity Therapeutics 723,416.35 Bn 723,416.32 Bn - -
2 Belite Bio 57,340.00 Bn 57,340.00 Bn - -
3 Quantum Biopharma 19,125.08 Bn 19,125.08 Bn - -
4 Legend Biotech 3,262.00 Bn 3,261.71 Bn 242.10 Mn 0.32
5 Akari Therapeutics 1,789.67 Bn 1,789.67 Bn - -
6 Evaxion A 1,480.39 Bn 1,480.37 Bn - -
7 Psyence Biomedical 241.78 Bn 241.78 Bn - -
8 Vertex Pharmaceuticals 113.54 Bn 106.29 Bn 2.59 Bn -
9 Abivax 94.26 Bn 94.26 Bn - -
10 OKYO Pharma 244.98 Mn 240.76 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2025 -0.15
Sep 30, 2024 0.00
Mar 31, 2024 -0.06
Sep 30, 2023 0.00